Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02747576 · ClinicalTrials.gov registry record
Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma
A clinical trial, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- 137
- Enrollment target
NCT02747576: Completed study, sponsored by St. Jude Children's Research Hospital.
NCT02747576 is a clinical trial that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 137 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02747576 has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- 137 participants
- Enrollment target
Study Summary
Survivors of pediatric medulloblastoma (MB) are at-risk for neurocognitive and social deficits, including specific skills such as facial affect recognition which is the ability to recognize the emotional expressions of another person. Because the underlying mechanisms of these deficits are poorly understood, the investigators propose to examine social-cognitive skills (i.e. facial affect recognition) and indices of brain integrity, including an established core neural network of face perception in MB survivors and healthy controls. By comparing these outcomes between survivors of MB and healthy controls, investigators seek to identify the areas of the brain that help individuals recognize emotions. Primary Objective: * To evaluate social cognition in adolescent and young adult survivors of pediatric medulloblastoma. Secondary Objective: * To examine indices of brain integrity and function and their association with facial affect recognition in survivors of pediatric medulloblastoma.
Primary Outcome
Mean scores on measures of facial affect recognition will be compared between survivors of medulloblastoma and age, sex, and race matched community controls.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2016-07-13 |
| Est. Completion | 2018-08-31 |
What the finished NCT02747576 record still lists
NCT02747576 is an observational study that tracks outcomes without assigning an intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02747576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02747576 about?
NCT02747576 is a clinical study titled "Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma". Survivors of pediatric medulloblastoma (MB) are at-risk for neurocognitive and social deficits, including specific skills such as facial affect recognition which is the ability to recognize the emotional expressions of another person. Because the underlying mechanisms of these deficits are poorly un...
What is the current status of trial NCT02747576?
This trial is currently completed. The enrollment target is 137 participants. The study started on 2016-07-13. Estimated completion is 2018-08-31.
Who is sponsoring clinical trial NCT02747576?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI